Dabrafenib (GSK2118436)

Catalog No.S2807

Dabrafenib (GSK2118436) Chemical Structure

Molecular Weight(MW): 519.56

Dabrafenib (GSK2118436) is a mutant BRAFV600 specific inhibitor with IC50 of 0.7 nM in cell-free assays, with 7- and 9-fold less potency against B-Raf(wt) and c-Raf, respectively.

Size Price Stock Quantity  
In DMSO USD 180 In stock
USD 90 In stock
USD 130 In stock
USD 170 In stock
USD 270 In stock
USD 400 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

8 Customer Reviews

  • BRAFi/MEKi-resistant A375DR and the parental A375 cells were treated with 2 μM vorinostat and/or the combination of 0.125 μM dabrafenib and 5 nM trametinib. Protein lysates were harvested after 72 hr. Western blot analysis was carried out for p-MEK and p-P90RSK as indicators of activation of MAPK pathway, ac-H3 as indicator for levels of acetylated histone H3 and a-tubulin as a loading control.

    Cell, 2018, 173(6):1413-1425. Dabrafenib (GSK2118436) purchased from Selleck.

    A375P cells were treated with vehicle, the BRAF inhibitor GSK2118436, the MEK inhibitor GSK1120212, 10 uM HCQ, or the indicated combinations. Shown are 48-hour immunoblots directed against the indicated proteins.

    J Clin Invest 2014 24(3), 1406-17. Dabrafenib (GSK2118436) purchased from Selleck.

  • Levels of pERK and tERK in the CLL cells derived from PBMC were measured by Western blot. We used vemurafenib, dabrafenib, and trametinib (0.07 uM) as indicated. One of 3 independent experiments with similar results is shown. CLL cells exposed to dabrafenib or vemurafenib had an elevated pERK/tERK ratio as compared with vehicle (P < 0.01).

    J Clin Invest 2014 124(11), 5074-84. Dabrafenib (GSK2118436) purchased from Selleck.

    Immunoblotting of whole-cell lysates of WM1366 exposed to the indicated drugs for 48 hours using specific antibodies for phospho-acetyl CoA carboxylase (p-ACC), total acetyl CoA carboxylase (t-ACC), phospho-ERK1/2 (p-ERK1/2), and total ERK1/2 (t-ERK1/2). Immunoblots were quantified using ImageJ. The ratio of phosphorylated to total protein normalized to control is shown above the respective blots.

    Clin Cancer Res, 2018, 24(5):1090-1102. Dabrafenib (GSK2118436) purchased from Selleck.

  • Western blots for untreated, early, and late tumors.

    Cancer research, 2018, 78(2):542-557. Dabrafenib (GSK2118436) purchased from Selleck.

    Dabrafenib alleviates acetaminophen-induced hepatotoxicity in mice. Mice were treated with 300 mg/kg acetaminophen (i.p.), with or without pretreatment with 300 mg/kg or 100 mg/kg dabrafenib (p.o.).TUNEL staining for nuclear DNA fragmentation in mouse liver cells.

    Cell Death Dis 2014 5, e1278. Dabrafenib (GSK2118436) purchased from Selleck.

  • The effects of inhibitors of mutant BRAFV600 inhibitor dabrafenib on cancer cell growth were evaluated by the MTT assay. Cell growth inhibition of FRO and SW1736 cell lines induced by dabrafenib.

    Transl Res 2014 10.1016/j.trsl.2014.06.005. Dabrafenib (GSK2118436) purchased from Selleck.

    Western blot analysis of p-Erk and total ERK in A375 melanoma cell line after treatment with different doses of Dabrafenib for 48 hours (A). p-ERK signal was normalized with total ERK signal (B), SD and means of the normalized p-ERK values were reported.

    PLoS One, 2016, 11(3):e0152104. Dabrafenib (GSK2118436) purchased from Selleck.

Purity & Quality Control

Choose Selective Raf Inhibitors

Biological Activity

Description Dabrafenib (GSK2118436) is a mutant BRAFV600 specific inhibitor with IC50 of 0.7 nM in cell-free assays, with 7- and 9-fold less potency against B-Raf(wt) and c-Raf, respectively.
Targets
B-Raf (V600E) [3]
(Cell-free assay)
B-Raf [3]
(Cell-free assay)
C-Raf [3]
(Cell-free assay)
0.7 nM 5.2 nM 6.3 nM
In vitro

Dabrafenib is selective for Raf kinase, with 400 fold selectivity towards B-Raf over 91% of the other kinases tested. Dabrafenib inhibits B-RafV600E kinase, leading to decreased ERK phosphorylation and inhibition of cell proliferationby an initial arrest in the G1 phase of the cell cycle in cancer cells that specifically encode the mutation for B-RafV600E. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
M37rW2tqdmG|ZTDBd5NigQ>? MnLSTY5pcWKrdHnvckBw\iCQLYTldo1qdmGuIFjpd{B1[WepZXSgRk1T[WZiVk[wNGUhdXW2YX70JIV5eHKnc4Pl[EBqdiCkYXP1cI93cXK3czDpcoZm[3SnZDDpcpNm[3RiY3XscJMh[29vZYjwdoV{e2mwZzDDSGM{PyCjc4Pld5Nm\CCjczDk[YNz\WG|ZTDpckBjcW:2aX75cIF1\WRvTVXLJJBzd3SnaX6gdIhwe3Cqb4L5cIF1cW:wIHL5JGFteGijU3Py[YVvKGG|c3H5JJdqfGhiSVO1NEBw\iByLkCwNFch|ryP MYOyOFkxODZ5Mx?=
SK-MEL-28 NYPzenp1U2mwYYPlJGF{e2G7 NYnLZ4x6OSCq M4\mcGlvcGmkaYTpc44hd2ZiQj3SZYYhXjZyMFWgcZV1[W62IHnuJIh2dWGwIGPLMW1GVC1{ODDj[YxteyCjc4Pld5Nm\CCjczDk[YNz\WG|ZTDpckBGWkticHjvd5Bpd3K7bHH0bY9vKHerdHigTWM2OCCxZjCwMlAxPCEQvF2= NX[x[WNEOjR7MEC2O|M>
HepG2 NEjkbXNMcW6jc3WgRZN{[Xl? NIDwUJhKdmirYnn0bY9vKG:oIFKtVoFnKFZ4MEDFJI12fGGwdDDpckBpfW2jbjDI[ZBIOiClZXzsd{Bie3Onc4Pl[EBieyCmZXPy[YF{\SCrbjDFVmsheGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iByLkCwOEDPxE1? NY\DWGtQOjR7MEC2O|M>
COLO205 NXvkRVlYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XucWlvcGmkaYTpc44hd2ZiaIXtZY4hS0:OT{KwOUBk\WyuIIDyc4xq\mW{YYTpc44hf2m2aDDJR|UxKG:oIECuNFA4KM7:TR?= M1Xw[|I1QTByNkez
HepG2 NIXlOXFHfW6ldHnvckBCe3OjeR?= M3PPWFQ2KG2rbh?= MX7EUXNQ NFXaPZBKdmirYnn0bY9vKG:oIFHsb|UhcW5iVFfGMYJmfGFvc4TpcZVt[XSnZDDoeY1idiCKZYDHNkBk\WyuczDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiCVbXHkNkBxcG:|cHjvdplt[XSrb36geJJm[XSnZDDmc5IhPDVibXnud{BxemmxcjD0c{BVT0ZvYnX0ZUB{fGmvdXzheIlwdiCvZXHzeZJm\CCjZoTldkA3OCCvaX7zJIJ6KG:meYPz[Zkh[myxdDDzZ4FvdmW{IHHuZYx6e2m|IIfpeIghUUN3MDDv[kA{NjdizszN MnHQNlQ6ODB4N{O=
HFF MkK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFztZVYyOCEQvF2= NEj5VIs4OiCq Mkm0SG1UVw>? MofTTY5pcWKrdHnvckBw\iCycn;sbYZmemG2aX;uJI9nKGi3bXHuJGhHTiClZXzsd{Bp[XKkb4Lpcochf2muZDD0fZBmKEJvUnHmJJdqfGhiSVO1NEBw\iB|IN88US=> NIf5UFQzOzh2NECzPC=>
SK-MEL-28 Ml2wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYmxNEDPxE1? NFnaO284OiCq M4fvSGROW09? MorITY5pcWKrdHnvckBw\iCELWLh[kBXPjByRTDteZRidnRvZILpeoVvKFONLV3FUE0zQCClZXzsJJBzd2yrZnXyZZRqd25id3n0bEBKSzVyIH;mJFAvODR|IN88US=> MUGyN|g1PDB|OB?=
A375P-F11 NXPlUFdoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPHT4syOCEQvF2= M4m5dVczKGh? NH\lbWZFVVOR MlXYTY5pcWKrdHnvckBw\iCELWLh[kBXPjByRTDteZRidnRvZILpeoVvKEF|N{XQMWYyOSClZXzsJJBzd2yrZnXyZZRqd25id3n0bEBKSzVyIH;mJFAvODdzIN88US=> NFrEPIQzOzh2NECzPC=>
MALME-3M MoDNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDibYxIOTBizszN NWH4dmVNPzJiaB?= MYPEUXNQ NX\nWJBTUUN3ME2xJI5O MXqyN|g1PDB|OB?=
UACC-62 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fHR|ExKM7:TR?= NVf0O25[PzJiaB?= MlvsSG1UVw>? MkjhTWM2OD1zIH7N M1;5ZVI{QDR2MEO4
C32TG M4nlTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXjNVAh|ryP NV7Lcm81PzJiaB?= M4XFdWROW09? NFLEOmtKSzVyPUGgcm0> MWeyN|g1PDB|OB?=
SK-MEL-1 NI\sTFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHmXIcyOCEQvF2= Ml[yO|IhcA>? MlGxSG1UVw>? NYLtWY1nUUN3ME2yJI5O NW\1bJV2OjN6NESwN|g>
M14 NXTUTIxnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFG1cY8yOCEQvF2= M3fTVVczKGh? M2TKVmROW09? NESz[|JKSzVyPUKgcm0> MkjaNlM5PDRyM{i=
SK-MEL-28 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7DS4YyOCEQvF2= M{CycVczKGh? NYDHTVJ2TE2VTx?= NXH6ZZRqUUN3ME2zJI5O MU[yN|g1PDB|OB?=
A375 NFHRb3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfGO3UyOCEQvF2= MYi3NkBp MXXEUXNQ M1P0SGlEPTB;NDDuUS=> NUXwe5JTOjN6NESwN|g>
DU-4475 M{XMZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXkb|kyOCEQvF2= NV7CTYhRPzJiaB?= M{i0N2ROW09? MX3JR|UxRTVibl2= M17Xe|I{QDR2MEO4
UACC-257 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{D4[lExKM7:TR?= MlzIO|IhcA>? M{\NU2ROW09? NVnuUnZPUUN3ME22JI5O M4T2eFI{QDR2MEO4
Colo 205 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\UNVAh|ryP NETZXoQ4OiCq NIGwW2RFVVOR Ml\WTWM2OD15IH7N NWDUeXlVOjN6NESwN|g>
SK-MEL-3 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVr3Z2g5OTBizszN MlftO|IhcA>? NGjmXnZFVVOR NUS0UZVWUUN3ME23JI5O MViyN|g1PDB|OB?=
SH-4 NX7TdWFCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2CyfVExKM7:TR?= NGCxZ4U4OiCq NIX4XXlFVVOR NXTW[3htUUN3ME24JI5O MmHjNlM5PDRyM{i=
A101D MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXuxNEDPxE1? MUm3NkBp MYTEUXNQ MnnNTWM2OD17IH7N NHPl[5YzOzh2NECzPC=>
ES-2 MlHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXH0U3gyOTBizszN NIq2RpY4OiCq MmTySG1UVw>? MU\JR|UxRTV|IH7N MVeyN|g1PDB|OB?=
HT-29 MnzyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjXNVAh|ryP MlTqO|IhcA>? NUHG[29QTE2VTx?= MojyTWM2OD14NjDuUS=> MYmyN|g1PDB|OB?=
SW1417 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYKxNEDPxE1? MWi3NkBp NITrcZZFVVOR NWryeYpbUUN3ME2xOVghdk1? MonUNlM5PDRyM{i=
SW872 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWOxNEDPxE1? M13LN|czKGh? M1;LfGROW09? MYnJR|UxRTN5NzDuUS=> NFOwNHMzOzh2NECzPC=>
RKO NGnnfJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGD1SmQyOCEQvF2= Ml:0O|IhcA>? M37wR2ROW09? NWHQNGtuUUN3ME2yMlUzOiEQvF2= M17SPVI{QDR2MEO4
A673 NIiyUnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{eyeFExKM7:TR?= MV:3NkBp NYnnRWoxTE2VTx?= MlXPTWM2OD1zMDFOwG0> M2L2UFI{QDR2MEO4
GCT MmjMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV[xNEDPxE1? MljHO|IhcA>? M3;FZWROW09? NHrHS|BKSzVyPUGwJO69VQ>? NEnFbHUzOzh2NECzPC=>
WM-115 M3mzR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYWxNEDPxE1? MWC3NkBp MnO0SG1UVw>? MV\JR|UxRTVibl2= NH\lTJozOzh2NECzPC=>
YUMAC NVf2fXRwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;L[VExKM7:TR?= MV:3NkBp MlvISG1UVw>? MkHiTWM2OD13IH7N NFXscY0zOzh2NECzPC=>
OV-90 NV\EeVBMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXmxNEDPxE1? M1zDelczKGh? NFjUU2xFVVOR M4X6V2lEPTB;Mkmgcm0> NEjxe5EzOzh2NECzPC=>
NCI-H508 NFfk[HFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXMRmRxOTBizszN NV3K[5k3PzJiaB?= MWTEUXNQ M3q1TGlEPTB;MUCg{txO M4\UUFI{QDR2MEO4
MDA-MB-231 NF;4PI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfNNHUyOCEQvF2= NHXUWFY4OiCq M1W4TmROW09? MXHJR|UxRTFyIN88US=> MVyyN|g1PDB|OB?=
SW756 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWflXWU2OTBizszN M2P6UVczKGh? NWnpPWVJTE2VTx?= MXrJR|UxRTFyIN88US=> M1vTZVI{QDR2MEO4
SW-837 MkPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWKxNEDPxE1? MXG3NkBp MnK2SG1UVw>? Ml3hTWM2OD1zMDFOwG0> Mlm3NlM5PDRyM{i=
UMUC-3 M1ewOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\1dJE{OTBizszN NEHGVXg4OiCq MVrEUXNQ M4\UT2lEPTB;MUCg{txO NIjFeFYzOzh2NECzPC=>
LS-174T NFzCdmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV2xNEDPxE1? NGTnWXU4OiCq NYH5c21[TE2VTx?= MX\JR|UxRTFyIN88US=> NH3YPZgzOzh2NECzPC=>
A549 NELJSXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3j5ZVExKM7:TR?= M1;rflczKGh? NEjVcHdFVVOR NXzKR|ZiUUN3ME2xNEDPxE1? NXvKWGI{OjN6NESwN|g>
SHP-77 NXvTZolmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3K0VFExKM7:TR?= M3XYRVczKGh? MWfEUXNQ NFe3SYhKSzVyPUGwJO69VQ>? M1ftOVI{QDR2MEO4
SW480 NUXWO5BrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HrZVExKM7:TR?= M37J[lczKGh? MlftSG1UVw>? MmnETWM2OD1zMDFOwG0> M3LzfVI{QDR2MEO4
DLD-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXexNEDPxE1? MXO3NkBp MVTEUXNQ MnnMTWM2OD1zMDFOwG0> NUXodmlkOjN6NESwN|g>
HCT-116 NHnlfHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTPNVAh|ryP NILvWm04OiCq MV\EUXNQ NWHzPXVtUUN3ME2xNEDPxE1? M13Y[FI{QDR2MEO4
NCI-H747 MmG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfhXIw5OTBizszN MYe3NkBp NWjpbXJDTE2VTx?= MXPJR|UxRTFyIN88US=> MVmyN|g1PDB|OB?=
T-84 MmHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1L4[VExKM7:TR?= NV\TNJpjPzJiaB?= NYHNW48xTE2VTx?= M3TxSWlEPTB;MUCg{txO M{\SZ|I{QDR2MEO4
NCI-H460 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;rNVAh|ryP NUe4blRyPzJiaB?= M4\ROGROW09? MYfJR|UxRTFyIN88US=> NEfrXXkzOzh2NECzPC=>
Calu-6 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWOxNEDPxE1? MVe3NkBp MljxSG1UVw>? M3PscmlEPTB;MUCg{txO NHT4OXUzOzh2NECzPC=>
HCC-2998 NIDwVJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1:wU|ExKM7:TR?= NUnFWpo4PzJiaB?= MVzEUXNQ NETJV3RKSzVyPUGwJO69VQ>? M4C5eFI{QDR2MEO4
LS1034 M1u1XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{Dv[FExKM7:TR?= MWW3NkBp NVLKUoFWTE2VTx?= MkLaTWM2OD1zMDFOwG0> M3vjR|I{QDR2MEO4
CHP-212 M4fCV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\RV4gyOCEQvF2= Mn\XO|IhcA>? M{jkRWROW09? NHTNfGZKSzVyPUGwJO69VQ>? NHPJfZMzOzh2NECzPC=>
SK-N-AS NXHUWYpDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13RWlExKM7:TR?= MljvO|IhcA>? NULkW3pSTE2VTx?= M{jP[2lEPTB;MUCg{txO MlnqNlM5PDRyM{i=
BFTC-905 Mm\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWSxNEDPxE1? MkTRO|IhcA>? M2fnbmROW09? NX\pdXdRUUN3ME2xNEDPxE1? MVqyN|g1PDB|OB?=
HuT78 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVGxNEDPxE1? MnzzO|IhcA>? M2rKS2ROW09? NGPYU2RKSzVyPUWyJI5O NYnscWRMOjN6NESwN|g>
RPMI-8226 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPldZIyOCEQvF2= MWe3NkBp NWT5O21rTE2VTx?= MkO0TWM2OD1{NkOgcm0> MoryNlM5PDRyM{i=
BC-3 NWLKSXZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGC0OZQyOCEQvF2= MYO3NkBp NF;IPG5FVVOR NGfIS4hKSzVyPUK3O{BvVQ>? NHSwU|UzOzh2NECzPC=>
ACHN M2fyemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3v4b|ExKM7:TR?= MVS3NkBp MYrEUXNQ NH7jXm9KSzVyPUK5OEBvVQ>? NGfOU3UzOzh2NECzPC=>
JRT3-T35 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVOxNEDPxE1? MYm3NkBp MmrQSG1UVw>? Mmm2TWM2OD1{OUWgcm0> NWiw[5RyOjN6NESwN|g>
SK-MES-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofZNVAh|ryP NF7OVVI4OiCq M3vEWGROW09? NViwe4pNUUN3ME2zNlkhdk1? NH:2fYEzOzh2NECzPC=>
CESS MoW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXSxNEDPxE1? NG\JXpY4OiCq M3rucGROW09? MVzJR|UxRTR7NzDuUS=> M2\uWlI{QDR2MEO4
H4 NG[3R2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TBb|ExKM7:TR?= NU\GcoNJPzJiaB?= NGL4RlBFVVOR Mm[yTWM2OD14MUmgcm0> NYCyZYI1OjN6NESwN|g>
BC-1 MkjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrKcIoyOCEQvF2= NYmx[nJwPzJiaB?= NE\LN5FFVVOR MV7JR|UxRTdyNDDuUS=> NWDZWI1POjN6NESwN|g>
DB MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYOxNEDPxE1? MW[3NkBp NV7ySWZpTE2VTx?= MU\JR|UxRTh5MzDuUS=> MVOyN|g1PDB|OB?=
RPMI-6666 M3TqOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWmxNEDPxE1? M2HCNlczKGh? NUm3WGlKTE2VTx?= M{\MemlEPTB;OUK4JI5O NUXxUIpkOjN6NESwN|g>
MC/CAR MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37CcVExKM7:TR?= M{fTdFczKGh? NX2x[5ZSTE2VTx?= MULJR|UxRTFwMECyJO69VQ>? NUXTVHhUOjN6NESwN|g>
SNU-1 NX;5cYVLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDyUmVzOTBizszN NIHkdIc4OiCq MlLKSG1UVw>? M3jXUWlEPTB;MT61NFEh|ryP Mn3FNlM5PDRyM{i=
CEM/C1 NYT1dXA2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPHZXEyOCEQvF2= M2HIXFczKGh? NU\iOo1KTE2VTx?= M1vicWlEPTB;MT63O|Mh|ryP NFnGXGQzOzh2NECzPC=>
GDM-1 NWnPTZFlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\DeVExKM7:TR?= NVrLbYlCPzJiaB?= MnPoSG1UVw>? Mo\6TWM2OD1zLkm5O{DPxE1? MWiyN|g1PDB|OB?=
HT-1080 NV7ZdJpDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\WNVAh|ryP MWi3NkBp M2H0UmROW09? M1TLe2lEPTB;Mj6wNFQh|ryP NXW4bnU6OjN6NESwN|g>
HL-60 NYCzcoVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3f1cFExKM7:TR?= NWrLdFduPzJiaB?= NUHKWJNoTE2VTx?= NULMfZprUUN3ME2yMlE4QCEQvF2= M4H4PVI{QDR2MEO4
C3A MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDyNVAh|ryP NF;hSZg4OiCq NXzvfo53TE2VTx?= NHXtdIFKSzVyPUWuOFE1KM7:TR?= M2XSblI{QDR2MEO4
MES-SA NXHvVXJIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFznOIYyOCEQvF2= NYixO4g2PzJiaB?= NYDjXIVxTE2VTx?= NV76RmZOUUN3ME22Mlk5QSEQvF2= M4DpRVI{QDR2MEO4
22Rv1 MkPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUGxNEDPxE1? M3jndVczKGh? NFm4R4FFVVOR Mn\QTWM2OD1zMDFOwG0> NWHTb5RWOjN6NESwN|g>
647-V NGKxXXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3f0bVExKM7:TR?= M3r0XFczKGh? NIryfYtFVVOR NWjJOpF7UUN3ME2xNEDPxE1? NHvrNW8zOzh2NECzPC=>
786-O NXvVeIhmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmn3NVAh|ryP M4D3OFczKGh? MnHpSG1UVw>? NIG3[Y9KSzVyPUGwJO69VQ>? NHjQbpIzOzh2NECzPC=>
A172 M1q3cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVmxNEDPxE1? MXe3NkBp MWfEUXNQ NEW1b3FKSzVyPUGwJO69VQ>? Mn:0NlM5PDRyM{i=
A204 NHr0PZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjicpgyOCEQvF2= NIHJ[5E4OiCq Mk\zSG1UVw>? NWPXSWhSUUN3ME2xNEDPxE1? M2fTSFI{QDR2MEO4
A427 NYrYXHV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\Y[FExKM7:TR?= MlTNO|IhcA>? NIHScoRFVVOR MUHJR|UxRTFyIN88US=> MmrRNlM5PDRyM{i=
A431 NYK1fWlPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPSUHVHOTBizszN M37VeVczKGh? NW\NOJltTE2VTx?= MX;JR|UxRTFyIN88US=> MYqyN|g1PDB|OB?=
A2780 MmTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrUNVAh|ryP NHjhdog4OiCq M{LOcGROW09? MmraTWM2OD1zMDFOwG0> MmrvNlM5PDRyM{i=
ARH-77 Ml\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXWxNEDPxE1? Mne0O|IhcA>? MXrEUXNQ M3\V[GlEPTB;MUCg{txO M12zRVI{QDR2MEO4
Be(2)C M4PSeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfnU4UyOCEQvF2= MYi3NkBp NV3vcnl3TE2VTx?= M33NWWlEPTB;MUCg{txO NIWzZpczOzh2NECzPC=>
BT-20 M{LkPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXSxNEDPxE1? MnH1O|IhcA>? M4G5U2ROW09? M2\COmlEPTB;MUCg{txO MmrCNlM5PDRyM{i=
BxPc3 NGXscFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn[yNVAh|ryP NH3ONXM4OiCq MorpSG1UVw>? NVzR[VBYUUN3ME2xNEDPxE1? MmXKNlM5PDRyM{i=
C-4 I NEHQSoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLORmxqOTBizszN MWe3NkBp NHnjRYdFVVOR MlfjTWM2OD1zMDFOwG0> MVqyN|g1PDB|OB?=
C33A NWC1TIZrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfjN4VnOTBizszN Mo\UO|IhcA>? NG\TWYpFVVOR M4HoNmlEPTB;MUCg{txO NYT2WoREOjN6NESwN|g>
CAL-27 M3vifWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\GNVAh|ryP M3HKVFczKGh? MX\EUXNQ NUfxTGpRUUN3ME2xNEDPxE1? MWKyN|g1PDB|OB?=
CAL-62 MkGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmT3NVAh|ryP NWTQW2dLPzJiaB?= NX\L[3hMTE2VTx?= MoKxTWM2OD1zMDFOwG0> NEHGOnIzOzh2NECzPC=>
Calu-3 NUfNOHFDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGThbXIyOCEQvF2= MX63NkBp M3;oOGROW09? M{DGdmlEPTB;MUCg{txO MojUNlM5PDRyM{i=
CaOV3 MojkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUGxNEDPxE1? MoO4O|IhcA>? NIPqVZZFVVOR MXnJR|UxRTFyIN88US=> MlS2NlM5PDRyM{i=
CGTHW1 M3HTNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jVbFExKM7:TR?= MkPXO|IhcA>? Ml64SG1UVw>? NIXzSo5KSzVyPUGwJO69VQ>? NYLwOHdmOjN6NESwN|g>
CHL-1 M4HjeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zSOVExKM7:TR?= MnfaO|IhcA>? MY\EUXNQ M{CzW2lEPTB;MUCg{txO Mn36NlM5PDRyM{i=
Colo320DM NFfFS5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nVdVExKM7:TR?= NEXwV|Q4OiCq MV;EUXNQ NFPK[3BKSzVyPUGwJO69VQ>? MlnPNlM5PDRyM{i=
Colo704 MlLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWGxNEDPxE1? M3nxOVczKGh? MmfhSG1UVw>? NHH6TXZKSzVyPUGwJO69VQ>? MX:yN|g1PDB|OB?=
COR-L23 NFTv[mpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUKxNEDPxE1? NGftZ|k4OiCq MoDESG1UVw>? MUXJR|UxRTFyIN88US=> MkjsNlM5PDRyM{i=
CRO-AP2 MlvyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUOxNEDPxE1? NUe1OHBqPzJiaB?= Mnn2SG1UVw>? M{fQdWlEPTB;MUCg{txO NHv2eG8zOzh2NECzPC=>
Daudi M3LlcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYOxNEDPxE1? NVrU[Yd6PzJiaB?= M3P4NWROW09? MYPJR|UxRTFyIN88US=> M3TMZ|I{QDR2MEO4
DOTC 24510 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfHNVAh|ryP NHvUZWM4OiCq NE[xSpBFVVOR M4Hz[GlEPTB;MUCg{txO M4nKblI{QDR2MEO4
DU-145 NXPjOFU3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHPNVAh|ryP M2rX[VczKGh? MoLnSG1UVw>? MluzTWM2OD1zMDFOwG0> M3\VXVI{QDR2MEO4
EB-3 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;5PVExKM7:TR?= NIrR[5I4OiCq M13uZmROW09? MmfxTWM2OD1zMDFOwG0> M{fMSlI{QDR2MEO4
EFM-19 M3[wdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLMNVAh|ryP MkPKO|IhcA>? MkLLSG1UVw>? NF7lVYZKSzVyPUGwJO69VQ>? NGnMc20zOzh2NECzPC=>
EKVX MkLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3e3SlExKM7:TR?= NV\PO|hSPzJiaB?= NEK1NXNFVVOR MYjJR|UxRTFyIN88US=> NISyR|AzOzh2NECzPC=>
FaDu M3vp[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVX0OZJYOTBizszN MWi3NkBp MknsSG1UVw>? NUW0e|FDUUN3ME2xNEDPxE1? MUGyN|g1PDB|OB?=
G401 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3ewOFExKM7:TR?= NWLEU3NFPzJiaB?= M1LGcGROW09? MX7JR|UxRTFyIN88US=> MlHvNlM5PDRyM{i=
HCC-70 NGP2Z2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHQSG5oOTBizszN NYfSXopWPzJiaB?= NHy0d|lFVVOR Mn\YTWM2OD1zMDFOwG0> Mk\yNlM5PDRyM{i=
HCC-1954 NE\EeoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rGR|ExKM7:TR?= NUXwbHhvPzJiaB?= NFnO[XRFVVOR NELBXnNKSzVyPUGwJO69VQ>? NIL2eFYzOzh2NECzPC=>
Hela MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInkTHIyOCEQvF2= MUG3NkBp NFrYS5VFVVOR M1vGU2lEPTB;MUCg{txO M{TpblI{QDR2MEO4
Hep3B M{DlTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrkfWM3OTBizszN MojQO|IhcA>? M4LrT2ROW09? NIT0VoVKSzVyPUGwJO69VQ>? MnziNlM5PDRyM{i=
HMCB NX7LVnhbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;p[2QyOCEQvF2= NYD2fYE4PzJiaB?= NEPQZnhFVVOR MlO1TWM2OD1zMDFOwG0> MmHjNlM5PDRyM{i=
HN5 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH[yZ5gyOCEQvF2= NVKzcXE3PzJiaB?= NXXCWVQxTE2VTx?= NWW2[|A4UUN3ME2xNEDPxE1? MkHLNlM5PDRyM{i=
HOS M3T5XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{G4WVExKM7:TR?= M3zweVczKGh? M2HnR2ROW09? NYrKNG1sUUN3ME2xNEDPxE1? MlH0NlM5PDRyM{i=
HPAF-II M2WxSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3js[|ExKM7:TR?= NXWyenVyPzJiaB?= MWLEUXNQ NHfWV5RKSzVyPUGwJO69VQ>? M{Du[lI{QDR2MEO4
Hs746.T MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHi5dlkyOCEQvF2= MXS3NkBp NFzSTmFFVVOR NF[zSXRKSzVyPUGwJO69VQ>? NFHzbVAzOzh2NECzPC=>
HT NXjrUohlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUCy[odbOTBizszN Mk\HO|IhcA>? M3qwRmROW09? NIfLdI9KSzVyPUGwJO69VQ>? MlOyNlM5PDRyM{i=
HT-3 MmDtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX:xNEDPxE1? Mn3DO|IhcA>? MmjaSG1UVw>? NYDIT2plUUN3ME2xNEDPxE1? Mm\BNlM5PDRyM{i=
HuNS-1 NHLoTGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HTWFExKM7:TR?= Ml;VO|IhcA>? M{TES2ROW09? NH[wUppKSzVyPUGwJO69VQ>? M4\NS|I{QDR2MEO4
IGROV1 MmLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\NUlExKM7:TR?= M3ficVczKGh? NEf0blBFVVOR NXvBeHZNUUN3ME2xNEDPxE1? NWC3coFOOjN6NESwN|g>
J82 MkXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvzRYh[OTBizszN NUXCUJN3PzJiaB?= M{O5eWROW09? MVHJR|UxRTFyIN88US=> MWSyN|g1PDB|OB?=
JM1 M2C5Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTiO2EyOCEQvF2= MmDiO|IhcA>? NXziUmhGTE2VTx?= MWXJR|UxRTFyIN88US=> NVW0OGJPOjN6NESwN|g>
Kato III MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX35TnJ6OTBizszN NVuwNGx4PzJiaB?= NYP1UolVTE2VTx?= MXrJR|UxRTFyIN88US=> NVTQZllsOjN6NESwN|g>
KHOS-240S MkTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PldlExKM7:TR?= NX\zbnZwPzJiaB?= NEHmcohFVVOR MV;JR|UxRTFyIN88US=> NGPsWngzOzh2NECzPC=>
KM-12 NWLrVoJwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDKNVAh|ryP MX[3NkBp MojXSG1UVw>? M2PjSGlEPTB;MUCg{txO NHG5OWMzOzh2NECzPC=>
KPL-1 M2TPbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUexNEDPxE1? NVLI[2ZTPzJiaB?= M1:xU2ROW09? MWXJR|UxRTFyIN88US=> NGDaZlczOzh2NECzPC=>
KYSE-30 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoKzNVAh|ryP MWO3NkBp MormSG1UVw>? NXH6fYkzUUN3ME2xNEDPxE1? NX7iR|VkOjN6NESwN|g>
LNCaP NUXMd|VVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXGyUW43OTBizszN NVLhW5RuPzJiaB?= Mo\PSG1UVw>? NYHWZWxJUUN3ME2xNEDPxE1? MWOyN|g1PDB|OB?=
MCF-7 NHfkR2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmn1NVAh|ryP M4\PSFczKGh? NYq1UZFyTE2VTx?= M2HyVGlEPTB;MUCg{txO M3rn[|I{QDR2MEO4
MC-IXC M1TD[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoG1NVAh|ryP MoXMO|IhcA>? NEnzdHZFVVOR NVfQU4hQUUN3ME2xNEDPxE1? MVeyN|g1PDB|OB?=
MDA-MB-175 VII NFnlUnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPwT5UyOCEQvF2= NVfsUWZ2PzJiaB?= NILaSGdFVVOR NXv0bnNVUUN3ME2xNEDPxE1? MYKyN|g1PDB|OB?=
MDA-MB-468 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVP6RVRpOTBizszN NVjUcWZQPzJiaB?= Ml7uSG1UVw>? NF\SbXBKSzVyPUGwJO69VQ>? NG\HVYkzOzh2NECzPC=>
MiaPaCa MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDQNVAh|ryP MUW3NkBp M3vrVGROW09? M2Twd2lEPTB;MUCg{txO NYLoWVRrOjN6NESwN|g>
Molt-4 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTJNVAh|ryP NU\p[IoxPzJiaB?= M1f0VWROW09? NYD4OXBNUUN3ME2xNEDPxE1? NHL4c2YzOzh2NECzPC=>
NCI-ADR/RES MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1:1bFExKM7:TR?= M13q[FczKGh? NWnZcmxuTE2VTx?= MUjJR|UxRTFyIN88US=> MnLsNlM5PDRyM{i=
NCI-H69 NGfyS4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzBNVAh|ryP M1TmTlczKGh? NHHzeHdFVVOR NYHO[4xCUUN3ME2xNEDPxE1? NHzDO2QzOzh2NECzPC=>
NCI-H82 NHfDb5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\FOWsyOCEQvF2= NXLsRXM1PzJiaB?= NYTycW0xTE2VTx?= NIfSSHdKSzVyPUGwJO69VQ>? Ml7zNlM5PDRyM{i=
NCI-N87 MorRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoqyNVAh|ryP Ml24O|IhcA>? MUDEUXNQ M3TReGlEPTB;MUCg{txO MXWyN|g1PDB|OB?=
NCI-H146 NH:2NGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHLSZZ3OTBizszN M2TK[FczKGh? MWDEUXNQ MWfJR|UxRTFyIN88US=> MWOyN|g1PDB|OB?=
NCI-H157 NFHIZ|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PxUFExKM7:TR?= Ml3zO|IhcA>? MkfFSG1UVw>? M4m1[GlEPTB;MUCg{txO MnfMNlM5PDRyM{i=
NCI-H187 M4rOTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnLNVAh|ryP M17TOlczKGh? NFry[mVFVVOR Mn3LTWM2OD1zMDFOwG0> NXTMcVNSOjN6NESwN|g>
NCI-H209 NYjYS4E5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkizNVAh|ryP NYjiW2dzPzJiaB?= NFmxcnpFVVOR M3fldmlEPTB;MUCg{txO Ml3UNlM5PDRyM{i=
NCI-H226 NUK1O4lyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXK0W5ljOTBizszN NGW5e244OiCq Mn;CSG1UVw>? Ml\QTWM2OD1zMDFOwG0> M3;ET|I{QDR2MEO4
NCI-H292 NVPndZdYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWiz[Ho2OTBizszN NXXlV49VPzJiaB?= NFjZXHVFVVOR NFLKO2VKSzVyPUGwJO69VQ>? NV\qSmZbOjN6NESwN|g>
NCI-H322 NWXlb2RQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWqxNEDPxE1? MYO3NkBp NHnleVBFVVOR M{i2WWlEPTB;MUCg{txO MkLZNlM5PDRyM{i=
NCI-H358 NHP4[pNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHq1eIQyOCEQvF2= NUjuW4tOPzJiaB?= MWLEUXNQ M3K0PGlEPTB;MUCg{txO NHXwdFAzOzh2NECzPC=>
NCI-H520 M3zz[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPVNVAh|ryP M3ewT|czKGh? MoO5SG1UVw>? NYPzcGNVUUN3ME2xNEDPxE1? MVqyN|g1PDB|OB?=
NCI-H526 M4fRSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVqxNEDPxE1? NGroVnQ4OiCq Ml\oSG1UVw>? NUDMcFJVUUN3ME2xNEDPxE1? MWeyN|g1PDB|OB?=
NCI-H630 NXL3ZYdST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnjeoUyOCEQvF2= MoPkO|IhcA>? NHLsT|RFVVOR M3;zemlEPTB;MUCg{txO NY\DOZFjOjN6NESwN|g>
NCI-H661 NEm2WHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XvfVExKM7:TR?= M3u0fVczKGh? Mof0SG1UVw>? NUPLdFF{UUN3ME2xNEDPxE1? NU\0eY9SOjN6NESwN|g>
NCI-H716 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoWyNVAh|ryP Ml;aO|IhcA>? NEHs[YZFVVOR MUXJR|UxRTFyIN88US=> Ml\xNlM5PDRyM{i=
NCI-H1563 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUC1UGFuOTBizszN MXq3NkBp NGHK[olFVVOR MWDJR|UxRTFyIN88US=> NHK4bHQzOzh2NECzPC=>
NCI-H1792 NX7GRmxkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLKS3VHOTBizszN NH;s[HY4OiCq NVjmfZB2TE2VTx?= NXzOTVlHUUN3ME2xNEDPxE1? MkHVNlM5PDRyM{i=
NCI-H2030 M1XmcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLDcpoyOCEQvF2= M3zoblczKGh? MYfEUXNQ MUTJR|UxRTFyIN88US=> MlTpNlM5PDRyM{i=
NCI-H2052 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnH0NVAh|ryP MoHZO|IhcA>? MWfEUXNQ NHHkWJBKSzVyPUGwJO69VQ>? MlzPNlM5PDRyM{i=
NCI-H2122 M{XEc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVqxNEDPxE1? MXm3NkBp NEG4PFZFVVOR MULJR|UxRTFyIN88US=> M{nSNlI{QDR2MEO4
NCI-H2228 M4XsfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TyTVExKM7:TR?= M1;yOVczKGh? NGLOS4FFVVOR MnTlTWM2OD1zMDFOwG0> NVTJUGFUOjN6NESwN|g>
OE-19 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2[zPVExKM7:TR?= Mo\FO|IhcA>? MmDtSG1UVw>? NXj4fJBVUUN3ME2xNEDPxE1? NWrBbGEyOjN6NESwN|g>
OE-21 NX:w[ZNmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLEbFIyOCEQvF2= NELsU4s4OiCq M3jwdGROW09? NWTjbmRRUUN3ME2xNEDPxE1? M{m4[lI{QDR2MEO4
OE-33 NXftN5poT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vOcFExKM7:TR?= MVW3NkBp M2nZXGROW09? MoT6TWM2OD1zMDFOwG0> M4LleFI{QDR2MEO4
OVCAR-3 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVKxNEDPxE1? MnjUO|IhcA>? NHziSGdFVVOR M2\abGlEPTB;MUCg{txO M2DYeVI{QDR2MEO4
OVCAR-4 NXXJ[5BOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYD5WlNvOTBizszN MUW3NkBp MkXFSG1UVw>? M{ntZmlEPTB;MUCg{txO M1v4blI{QDR2MEO4
OVCAR-5 NU\Hdo5bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVSxNEDPxE1? M1\tVlczKGh? NYTtb4FZTE2VTx?= MWDJR|UxRTFyIN88US=> M13yNFI{QDR2MEO4
P3HR-1 M3zpZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXIe3dROTBizszN NVf2VXNvPzJiaB?= NXfLXpVsTE2VTx?= Mln6TWM2OD1zMDFOwG0> NGPL[5EzOzh2NECzPC=>
PC-3 NU\SO|lkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;oXIkyOCEQvF2= NXW1[JZYPzJiaB?= NELPd5hFVVOR NH3CSmdKSzVyPUGwJO69VQ>? NH7MbYszOzh2NECzPC=>
Raji NWnhSmNWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUSxNEDPxE1? M1e2[lczKGh? M{DpXGROW09? NYTlb5B2UUN3ME2xNEDPxE1? MU[yN|g1PDB|OB?=
RD MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrDNVAh|ryP NID0bng4OiCq M{LBe2ROW09? MkS4TWM2OD1zMDFOwG0> NGTTVmYzOzh2NECzPC=>
RD-ES MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUX1fpo{OTBizszN MlX3O|IhcA>? M3zQWGROW09? NEXyTW9KSzVyPUGwJO69VQ>? NF7wOVIzOzh2NECzPC=>
RL MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\lTFExKM7:TR?= M3[0e|czKGh? NFLSWFdFVVOR Mlm2TWM2OD1zMDFOwG0> M3nsVVI{QDR2MEO4
SaOS2 M1TlWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlr2NVAh|ryP NGrUW3U4OiCq M2LxbWROW09? NEPxeI9KSzVyPUGwJO69VQ>? MW[yN|g1PDB|OB?=
SCC-9 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fMNVExKM7:TR?= M1u3[lczKGh? MW\EUXNQ NHXncIdKSzVyPUGwJO69VQ>? MW[yN|g1PDB|OB?=
SCC-12 NGTVfmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofuNVAh|ryP MlHmO|IhcA>? MlTBSG1UVw>? NGPHSVRKSzVyPUGwJO69VQ>? NFjKTpkzOzh2NECzPC=>
SCC-13 NUKxVGNOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWixNEDPxE1? NHvjRWQ4OiCq M2DpOWROW09? NUW2VlU{UUN3ME2xNEDPxE1? Ml;aNlM5PDRyM{i=
SCC-15 M{\SVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUWxNEDPxE1? NGXKblE4OiCq NIXFb3NFVVOR NFLxZYRKSzVyPUGwJO69VQ>? MWqyN|g1PDB|OB?=
SCC-25 MlHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLa[4k{OTBizszN NEPjbmU4OiCq M{jhVmROW09? M4WyfmlEPTB;MUCg{txO NWDTVYpIOjN6NESwN|g>
SCLC-3 M3HRW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXKxNEDPxE1? MXO3NkBp NFzlZXpFVVOR NHHnNXJKSzVyPUGwJO69VQ>? NV;o[ZltOjN6NESwN|g>
SF-268 NYTXXld4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLjWWM1OTBizszN M33tV|czKGh? MVPEUXNQ MWXJR|UxRTFyIN88US=> M2O4[VI{QDR2MEO4
SF-295 NEj3e5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYixNEDPxE1? M3jmcVczKGh? M2n1ZmROW09? NXHKTmo2UUN3ME2xNEDPxE1? NWi4cIZGOjN6NESwN|g>
SJRH30 NYLlW5NbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWK4eFVOOTBizszN MlrzO|IhcA>? NUD0WHZHTE2VTx?= NWPaOoJLUUN3ME2xNEDPxE1? MVeyN|g1PDB|OB?=
SK-BR-3 NXHvfVY3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVGxNEDPxE1? MUC3NkBp NEKx[mlFVVOR Mm\JTWM2OD1zMDFOwG0> MV:yN|g1PDB|OB?=
SK-LMS-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVixNEDPxE1? NX7GZ2pNPzJiaB?= MoHDSG1UVw>? NGfVSGhKSzVyPUGwJO69VQ>? Mn\uNlM5PDRyM{i=
SK-N-DZ NV65SpdMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYKxNEDPxE1? NWXHUnh5PzJiaB?= NWn2SFBMTE2VTx?= M3nyRmlEPTB;MUCg{txO NXyyOndwOjN6NESwN|g>
SK-N-F1 NFzDemtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M32wO|ExKM7:TR?= NH31[244OiCq M3zwO2ROW09? NH:4UItKSzVyPUGwJO69VQ>? M2\5Z|I{QDR2MEO4
SKOV-3 NUG5S5RpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LmT|ExKM7:TR?= NV22XXVqPzJiaB?= M3yyfWROW09? NIG1T|JKSzVyPUGwJO69VQ>? NIrMblUzOzh2NECzPC=>
SK-UT-1 NGrtVlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvlNnEyOCEQvF2= Mn34O|IhcA>? NW\aWXd[TE2VTx?= MXXJR|UxRTFyIN88US=> NXjSWFU2OjN6NESwN|g>
SN12C NELMToRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\jRlExKM7:TR?= MkHuO|IhcA>? MXHEUXNQ NH3EPZVKSzVyPUGwJO69VQ>? NX;PXlhqOjN6NESwN|g>
SNB-19 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX:xNEDPxE1? MlX4O|IhcA>? NIezRpRFVVOR MlnuTWM2OD1zMDFOwG0> MoTLNlM5PDRyM{i=
SNU-5 NFT1dINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\WT5Z2OTBizszN MUe3NkBp NFL2em5FVVOR NWf3dHNJUUN3ME2xNEDPxE1? NUjjdnBHOjN6NESwN|g>
SNU-16 MlHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUSxNEDPxE1? M3nO[VczKGh? NHz3SZZFVVOR MWrJR|UxRTFyIN88US=> NYj1b2dkOjN6NESwN|g>
SNU-398 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnhV4kyOCEQvF2= MV63NkBp M1vOTGROW09? MkfGTWM2OD1zMDFOwG0> NXjH[2NuOjN6NESwN|g>
SNU-449 MkDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XENVExKM7:TR?= MlnsO|IhcA>? M{PJdGROW09? NVnGTmV[UUN3ME2xNEDPxE1? M2i3blI{QDR2MEO4
SR NFrFcIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDFNVAh|ryP NFO2[no4OiCq M1HKXWROW09? MYLJR|UxRTFyIN88US=> NFKxdmUzOzh2NECzPC=>
ST486 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PaV|ExKM7:TR?= MUW3NkBp NYXGRW5zTE2VTx?= NWTrWYlyUUN3ME2xNEDPxE1? M{XnTFI{QDR2MEO4
SW579 MnXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXkNVAh|ryP NVjaO5BVPzJiaB?= M1;OW2ROW09? NHi1PXhKSzVyPUGwJO69VQ>? NH60fGkzOzh2NECzPC=>
SW684 MkOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HBbFExKM7:TR?= M3HOVlczKGh? MXfEUXNQ NETlN2tKSzVyPUGwJO69VQ>? MYGyN|g1PDB|OB?=
SW-780 M37K[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4juWVExKM7:TR?= MX23NkBp NWfmV3I{TE2VTx?= NHuwTHBKSzVyPUGwJO69VQ>? MknrNlM5PDRyM{i=
SW900 NInJXYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jPbFExKM7:TR?= MkXHO|IhcA>? MWDEUXNQ M1LESGlEPTB;MUCg{txO MlrwNlM5PDRyM{i=
SW1088 NFKz[XpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXrSW9IOTBizszN M1;LSlczKGh? MlHkSG1UVw>? M3nPXWlEPTB;MUCg{txO M4nZbVI{QDR2MEO4
SW1463 NY\6fYhrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\JVXFlOTBizszN NUnGbWNEPzJiaB?= Mo\kSG1UVw>? NFOzbWdKSzVyPUGwJO69VQ>? NVXGU29mOjN6NESwN|g>
SW1990 NF3OUWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LuOFExKM7:TR?= NVz2NmFPPzJiaB?= MVTEUXNQ NHzDXFJKSzVyPUGwJO69VQ>? MkfJNlM5PDRyM{i=
T47D NGe0UG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLBcolzOTBizszN MXK3NkBp MkPoSG1UVw>? M2TxSWlEPTB;MUCg{txO MkW2NlM5PDRyM{i=
TE381.T NF7pNGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPxNVAh|ryP MUG3NkBp MX;EUXNQ NUjOdFJSUUN3ME2xNEDPxE1? MkHWNlM5PDRyM{i=
TK-10 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWqzNnBIOTBizszN M13ubFczKGh? M1PhWmROW09? MnPuTWM2OD1zMDFOwG0> NVPi[lU3OjN6NESwN|g>
U2OS MoD3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrETHIyOCEQvF2= M4PjWlczKGh? NV\4R5I5TE2VTx?= Ml71TWM2OD1zMDFOwG0> NHvzN2IzOzh2NECzPC=>
U251 NY\3Tm1YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofSNVAh|ryP NU\PNmx2PzJiaB?= NVWwWJJsTE2VTx?= NVXjTY1KUUN3ME2xNEDPxE1? NGXtdGozOzh2NECzPC=>
UACC-812 NIm1R4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXv5U2tOOTBizszN NIfqPWg4OiCq MnrFSG1UVw>? MVTJR|UxRTFyIN88US=> NWrR[GFQOjN6NESwN|g>
YAPC MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPSSZF{OTBizszN M{n0dVczKGh? MVXEUXNQ MYTJR|UxRTFyIN88US=> NV;jZYduOjN6NESwN|g>
ZR-75-1 NVjZTI9GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDNblIyOCEQvF2= NX:zOVN5PzJiaB?= MlzkSG1UVw>? NV;lPVdzUUN3ME2xNEDPxE1? MUmyN|g1PDB|OB?=
A375 NFLFWnlHfW6ldHnvckBie3OjeR?= MoPmNU4zKM7:TR?= NYHZTFdHPCCq MULEUXNQ MmXRTY5pcWKrdHnvckBw\iCyaH;zdIhwenmuYYTpc44hd2ZiTVXLMEBGWktuIHHu[EBUPlB? MnH0NlI{QDl2N{G=
YUSIT1 MVTGeY5kfGmxbjDhd5NigQ>? NVvMRmNVTE2VTx?= MVny[YR2[2WmIIPlcpNqfGm4aYT5JJdqfGhiSVO1NEA,KDBwNTFOwG0> NEnm[GUzOjN6OUS3NS=>
MeWo NHHNV3hIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MonCSG1UVw>? MVXJR|UxKD1iOUi3JI5O MmHUNlYxOTh3MkS=
WiDr NWKyO2RpT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NVzXWpFqTE2VTx?= MnXQTWM2OCB;IEe2JI5O NVn4[WNsOjZyMUi1NlQ>
Colo-205 MUDGeY5kfGmxbjDhd5NigQ>? NYHpdItUOSEQvF2= Mn7EOEBl NGC4RYZFVVOR NHTPXXlKdmS3Y3XkJIEhcGmpaHz5JINwdXCjcnHicIUh[2:vcHHjeIlwdiCyaHXuc5R6eGV? Mnu3NlU{QDFzNUK=
RBW-1 MXzGeY5kfGmxbjDhd5NigQ>? Mmj0NUDPxE1? M3rSSGROW09? Ml\NUo8hemWmdXP0bY9vKG:oIF3lb{AyNzJicHjvd5Bpd3K7bHH0bY9v M4LOeVI1QDh3Nkmw
RBO-1 MYPGeY5kfGmxbjDhd5NigQ>? MoqyNUDPxE1? M3G2N2ROW09? NWHwfHhwUW6qaXLpeIlwdiCxZjDN[YshOS9{IIDoc5NxcG:{eXzheIlwdg>? NXLtPYdSOjR6OEW2PVA>
RBO-2 NE[1O2FHfW6ldHnvckBie3OjeR?= MnThNUDPxE1? M{D2fGROW09? NW\zdJpqUW6qaXLpeIlwdiCxZjCgUYVsKDFxMjDwbI9{eGixconsZZRqd25? M{S0WVI1QDh3Nkmw
RBOW MlHzSpVv[3Srb36gZZN{[Xl? MnS4NUDPxE1? M1vUcWROW09? MX\Jcohq[mm2aX;uJI9nKCCPZXugNU8zKHCqb4PwbI9zgWyjdHnvci=> NFTKc2szPDh6NU[5NC=>
M257 M1\LXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\ybppxOTByIH7N NX\PSoFDPzJiaB?= MW\Ec4V{KG6xdDDpcohq[mm2IIDyc4xq\mW{YYTpc44hd2ZiTUK1O{Bk\WyuIHjhdoJwfXKrbnege4lt\CC2eYDlJGJTSUZ? Mn7ZNlM{OTd2NE[=
LCP MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlP1NVAxKG6P Ml;FO|IhcA>? MWrJcohq[mm2aX;uJI9nKHC{b3zp[oVz[XSrb36gc4YhVEOSIHPlcIwhcGG{Yn;1dolv\yCEUlHGJHY3ODCUIH31eIFvfGG2aX;u M4LrfFI{OzF5NES2
WM266 NULocYRoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\DSHptOTByIH7N NH7IR444OiCq Mnq0TY5pcWKrdHnvckBw\iCycn;sbYZmemG2aX;uJI9nKFePMk[2JINmdGxiaHHyZo92emmwZzDCVmFHKFZ4MEHEJI12fGGwdHH0bY9v NW[wc3F4OjN|MUe0OFY>
M257 NXr3WXhqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jtR|ExOCCwTR?= MlPYO|IhcA>? MYPEc4V{KG6xdDDpcohq[mm2IFXST|EuOiCyaH;zdIhwenmuYYTpc44hcW5iTUK1O{Bk\WyuIHjhdoJwfXKrbnege4lt\CC2eYDlJGJTSUZ? M1PWOlI{OzF5NES2
LCP M{izO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV:xNFAhdk1? MmjSO|IhcA>? M4nobWlvcGmkaYSgSXJMOS1{IIDoc5NxcG:{eXzheIlwdiCrbjDMR3Ah[2WubDDoZZJjd3W{aX7nJGJTSUZiVk[wNHIhdXW2YX70ZZRqd25? MnrUNlM{OTd2NE[=
WM266 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW[xNFAhdk1? NY\SdlFGPzJiaB?= M1XXOmlvcGmkaYSgSXJMOS1{IIDoc5NxcG:{eXzheIlwdiCrbjDXUVI3PiClZXzsJIhiemKxdYLpcochSlKDRjDWOlAxTCCvdYThcpRifGmxbh?= MoCxNlM{OTd2NE[=

... Click to View More Cell Line Experimental Data

In vivo Dabrafenib (orally administrated) inhibits the growth of B-RafV600E mutant melanoma (A375P) and colon cancer (Colo205) human tumor xenografts, growing subcutaneously in immuno-compromised mice. [1]

Protocol

Solubility (25°C)

In vitro DMSO 30 mg/mL (57.74 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% PEG400+0.5% Tween80+5% propylene glycol
For best results, use promptly after mixing.
8 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 519.56
Formula

C23H20F3N5O2S2

CAS No. 1195765-45-7
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01153763 Completed Melanoma GlaxoSmithKline August 9 2010 Phase 2
NCT02858921 Recruiting Melanoma Melanoma Institute Australia|Merck Sharp & Dohme Corp.|Novartis November 8 2017 Phase 2
NCT01978236 Terminated Melanoma and Brain Metastases GlaxoSmithKline April 8 2014 Phase 2
NCT01682083 Active not recruiting Melanoma Novartis Pharmaceuticals|Novartis January 8 2013 Phase 3
NCT01340833 Completed Cancer GlaxoSmithKline June 8 2011 Phase 1
NCT01723202 Active not recruiting Follicular Thyroid Cancer|Insular Thyroid Cancer|Papillary Thyroid Cancer|Recurrent Thyroid Cancer Manisha Shah|National Comprehensive Cancer Network|Ohio State University Comprehensive Cancer Center November 7 2012 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Raf Signaling Pathway Map

Raf Inhibitors with Unique Features

Related Raf Products3

Tags: buy Dabrafenib (GSK2118436) | Dabrafenib (GSK2118436) supplier | purchase Dabrafenib (GSK2118436) | Dabrafenib (GSK2118436) cost | Dabrafenib (GSK2118436) manufacturer | order Dabrafenib (GSK2118436) | Dabrafenib (GSK2118436) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID